Memory CD8 T cells are a critical component of protective immunity, and inducing effective memory T-cell responses is a major goal of vaccines against chronic infections and tumours 1-3 . Considerable effort has gone into designing vaccine regimens that will increase the magnitude of the memory response, but there has been minimal emphasis on developing strategies to improve the functional qualities of memory T cells 4 . Here we show that mTOR (mammalian target of rapamycin 5 , also known as FRAP1) is a major regulator of memory CD8 T-cell differentiation, and in contrast to what we expected, the immunosuppressive drug rapamycin has immunostimulatory effects on the generation of memory CD8 T cells. Treatment of mice with rapamycin following acute lymphocytic choriomeningitis virus infection enhanced not only the quantity but also the quality of virus-specific CD8 T cells. Similar effects were seen after immunization of mice with a vaccine based on non-replicating virus-like particles. In addition, rapamycin treatment also enhanced memory T-cell responses in non-human primates following vaccination with modified vaccinia virus Ankara. Rapamycin was effective during both the expansion and contraction phases of the T-cell response; during the expansion phase it increased the number of memory precursors, and during the contraction phase (effector to memory transition) it accelerated the memory T-cell differentiation program. Experiments using RNA interference to inhibit expression of mTOR, raptor (also known as 4932417H02Rik) or FKBP12 (also known as FKBP1A) in antigen-specific CD8 T cells showed that mTOR acts intrinsically through the mTORC1 (mTOR complex 1) pathway to regulate memory T-cell differentiation. Thus these studies identify a molecular pathway regulating memory formation and provide an effective strategy for improving the functional qualities of vaccine-or infection-induced memory T cells.
Memory CD8 T cells are a critical component of protective immunity, and inducing effective memory T-cell responses is a major goal of vaccines against chronic infections and tumours [1] [2] [3] . Considerable effort has gone into designing vaccine regimens that will increase the magnitude of the memory response, but there has been minimal emphasis on developing strategies to improve the functional qualities of memory T cells 4 . Here we show that mTOR (mammalian target of rapamycin 5 , also known as FRAP1) is a major regulator of memory CD8 T-cell differentiation, and in contrast to what we expected, the immunosuppressive drug rapamycin has immunostimulatory effects on the generation of memory CD8 T cells. Treatment of mice with rapamycin following acute lymphocytic choriomeningitis virus infection enhanced not only the quantity but also the quality of virus-specific CD8 T cells. Similar effects were seen after immunization of mice with a vaccine based on non-replicating virus-like particles. In addition, rapamycin treatment also enhanced memory T-cell responses in non-human primates following vaccination with modified vaccinia virus Ankara. Rapamycin was effective during both the expansion and contraction phases of the T-cell response; during the expansion phase it increased the number of memory precursors, and during the contraction phase (effector to memory transition) it accelerated the memory T-cell differentiation program. Experiments using RNA interference to inhibit expression of mTOR, raptor (also known as 4932417H02Rik) or FKBP12 (also known as FKBP1A) in antigen-specific CD8 T cells showed that mTOR acts intrinsically through the mTORC1 (mTOR complex 1) pathway to regulate memory T-cell differentiation. Thus these studies identify a molecular pathway regulating memory formation and provide an effective strategy for improving the functional qualities of vaccine-or infection-induced memory T cells.
Rapamycin is an immunosuppressive drug commonly used in transplant recipients and specifically inhibits the intracellular kinase mTOR 5 . Several recent studies have shown that rapamycin has various effects on the immune system, such as inhibiting type I interferon production by plasmacytoid dendritic cells 6 , modulating T-cell trafficking 7 , and regulating Foxp3 expression in regulatory T cells 8, 9 . However, the role of the mTOR pathway in regulating CD8 T-cell responses is not known. To address this issue, we treated B6 mice with rapamycin during the course of an acute lymphocytic choriomeningitis virus (LCMV) infection, and monitored the virus-specific CD8 T-cell response ( Fig. 1a ). We made the surprising observation that rapamycin enhanced the LCMV-specific CD8 T-cell response. Increased numbers of antigen-specific CD8 T cells were seen in both lymphoid and nonlymphoid tissues ( Fig. 1a and Supplementary Fig. 1 ). The most notable thing about this result was the decreased contraction of the T-cell response in the rapamycin treated group. Similar frequencies of virus-specific effector CD8 T cells were observed in both groups of mice at the peak of the T-cell response on day 8 post-infection, but there was minimal contraction of the T cells in the rapamycin treated group ( Fig. 1a ). To determine whether the decreased T-cell contraction seen between days 8 to 30 post-infection in the rapamycin treated group was due to increased cell proliferation and/or reduced cell death, mice were infected with LCMV in the presence or absence of rapamycin and then given 5-bromodeoxyuridine (BrdU) during the T-cell contraction phase from days 10 to 22 ( Supplementary Fig. 2 ). We found that there was minimal incorporation of BrdU by antigen-specific CD8 T cells in either group of mice, showing that the decreased contraction of T cells in the presence of rapamycin was not due to increased cell proliferation.
Thus, it appears that the major effect of rapamycin is to enhance the survival of antigen-specific CD8 T cells.
We next examined the phenotype of the memory CD8 T cells present in the two groups of mice at day 36 post-infection ( Fig. 1b ). To investigate this, we performed phenotypic analysis of virusspecific memory CD8 T cells using four markers that are useful in defining memory CD8 T cells: CD127 (IL-7 receptor a and essential for memory T-cell maintenance [10] [11] [12] [13] ), CD62L (lymph node homing receptor and associated with high proliferative capacity 14 ), KLRG1 (inversely correlated with long lived memory cells 15, 16 ), and Bcl2 (anti-apoptotic and expressed at high levels in memory T cells 12, 17 ). Memory CD8 T cells generated in the presence of rapamycin expressed higher levels of CD127, CD62L and Bcl2, and had a higher frequency of KLRG1 Low cells compared to control mice ( Fig. 1b and Supplementary Fig. 3 ). These data strongly suggested that inhibition of the mTOR pathway using rapamycin not only increased the magnitude of the virus-specific CD8 T-cell response ( Fig. 1a ) but also improved the functional qualities of the memory CD8 T cells, as memory cells with the phenotype (CD127 High CD62L High Bcl2 High and KLRG1 Low ) are associated with long-lived protective immunity [14] [15] [16] . To test this directly, we examined the ability of these memory CD8 T cells to undergo homeostatic proliferation, a property essential for long-term memory maintenance, and to make recall responses upon re-exposure to antigen. As shown in Fig. 1c and d , virus-specific memory CD8 T cells generated in mice treated with rapamycin were superior to memory cells generated in untreated mice in both of these hallmark memory properties.
In the experiment shown in Fig. 1 , mice were continuously treated with rapamycin during the entire course of the T-cell response (days 21 to 35 post-infection). We next examined how rapamycin would effect the CD8 T-cell response if it was only given during the T-cell expansion phase (days 21 to 8 post-infection). These results ( Fig. 2a and b) were strikingly similar to what we had seen earlier ( Fig. 1a) ; even if the rapamycin treatment was discontinued during the contraction phase (days 8-30), there was only minimal death of the effector CD8 T cells generated in the presence of the drug. Previous studies have shown that the day 8 effector CD8 T-cell population consists of two subsets; the terminal effector T cells (CD127 Low , KLRG1 High ) that mostly die over the ensuing 2-4 weeks and the memory precursor cells (CD127 High , KLRG1 Low ) that mostly survive and further differentiate to give rise to the pool of long-lived memory cells 10, 15, 16 . Our results suggested that rapamycin was enhancing the formation of these memory precursor cells. This was indeed the case, and day 8 virus-specific effector CD8 T cells generated in rapamycin treated mice contained a higher proportion of CD127 High KLRG1 Low cells and these cells also expressed higher levels of Bcl2 ( Fig. 2c ). However, we noticed that the phenotype of memory CD8 T cells at day 36 post-infection was similar in the drug treated and control mice ( Fig. 2d ). This was different to the results obtained on continuous rapamycin treatment (compare Fig. 1b and Fig. 2d ). Taken together, these results clearly show that rapamycin enhances the formation of memory precursors during the naive to effector T-cell differentiation phase, but these results also suggest that rapamycin may also regulate the effector to memory transition phase.
To test this hypothesis, we treated mice with rapamycin only during the T-cell contraction phase (days 8-35) following acute LCMV infection ( Fig. 3 ). We found that the number of memory cells generated was not affected by the drug (Fig. 3a ) but the phenotype of these memory CD8 T cells was notably different (Fig. 3b ). Thus, rapamycin treatment during the effector to memory transition phase enhanced the memory differentiation program, resulting in a significantly higher number of virus-specific CD8 T cells with the phenotype characteristic of highly functional memory cells (P , 0.0001-0.0022; Fig. 3b ). It was important to determine if this represented cell proliferation and outgrowth of a subset of effector CD8 T cells already expressing these memory markers, or if rapamycin truly increased the expression of these markers in the surviving effector T cells during this effector to memory differentiation phase. To address this issue, we transferred a highly purified (.99.7%) and CFSE-labelled population of day 8 CD62L Low antigen-specific effector CD8 T cells into naive mice, and monitored both cell division and memory differentiation of these transferred effector cells in the presence or absence of rapamycin ( Fig. 3c ). We found that there was no cell division during this effector to memory transition phase (days 1-25 post-transfer) but that the memory T cells that differentiated in the presence of rapamycin reexpressed CD62L much faster ( Fig. 3d and e ). More importantly, these memory CD8 T cells were functionally superior and exhibited better recall responses and protective immunity (viral control) following challenge with vaccinia virus expressing the LCMV GP33 epitope ( Fig. 3f-h) . Thus, inhibiting mTOR during the effector to memory transition phase improved the functional qualities of memory T cells.
The results so far have shown that rapamycin can enhance both the magnitude and quality of the CD8 T-cell response following a primary viral infection. We next examined whether similar effects would be seen during a secondary response. As shown in Supplementary Fig. 4 , rapamycin also enhanced recall responses when the drug treatment was only done during secondary LCMV infection. Thus, rapamycin regulates both primary and secondary T-cell responses, and this has important implications in designing strategies for improving memory T-cell qualities during prime-boost vaccine regimens.
To determine if our findings from the mouse model of LCMV infection could be generalized to other systems, we examined the effect of rapamycin following immunization of mice with a nonreplicating vaccine. In these experiments, mice were vaccinated with virus-like particles (VLPs) derived from hepatitis B core antigen genetically fused to the LCMV GP33 epitope 18 . Rapamycin again enhanced both the magnitude and the quality of the VLP-induced memory CD8 T cells ( Supplementary Fig. 5 ). It should be noted that the effects of rapamycin treatment were very long-lasting; memory T-cell numbers remained tenfold higher even 165 days after stopping the drug treatment ( Supplementary Fig. 5a ). We also tested the applicability of this approach in a non-human primate model. Rhesus macaques previously immunized with vaccinia virus were boosted with modified vaccinia virus Ankara (MVA) in the presence or absence of rapamycin, and antigen-specific CD8 T-cell responses were analysed by intracellular IFN-c staining. We found clear differences in frequencies of antigen-specific CD8 T cells between rapamycin treated and untreated monkeys. In the presence of rapamycin, maintenance of a higher number of memory CD8 T cells was observed ( Supplementary Fig. 6a, b) , and slower T-cell contraction was evident compared to control animals ( Supplementary Fig. 6c ). These results demonstrate that rapamycin enhances T-cell immunity in both mice and non-human primates following vaccination with either live or inactivated vaccines.
Our results clearly establish that mTOR is a major regulator of memory CD8 T-cell differentiation. However, a critical question that needs to be answered is whether mTOR is acting intrinsically in antigen-specific CD8 T cells to regulate memory differentiation, or if the observed effects of rapamycin on memory formation are mediated by some other cells of the immune system. It is important to resolve this issue, as mTOR is ubiquitously expressed by many cells and several recent studies have shown that rapamycin can modulate the functional properties of several other cells of the immune system 6, 8, 9, 19, 20 . To address this question, we used a retrovirus based RNA shaded area) (2Rapa, n 5 9 mice; 1Rapa, n 5 9). b, Phenotypic changes in endogenous DbGP33 tetramer positive CD8 T cells in spleen on day 36 post LCMV infection (n 5 12; each group). B6 mice were treated with rapamycin during the effector to memory T-cell transition period (days 8-35 post-infection). MFI, mean fluorescence intensity. c, CD62L 2 day 8 P14 transgenic effector CD8 T cells were purified, labelled with CFSE, and then adoptively transferred into naive mice. Half of these mice were treated with rapamycin after transfer, and d, CD62L conversion in the antigen specific CD8 T cells was analysed longitudinally in the blood. e, CFSE profile and CD62L expression on antigen-specific memory CD8 T cells in the spleen at day 27 after transfer of CD62L 2 effector T cells. f, CD62L 2 day 8 P14 transgenic effector CD8 T cells were adoptively transferred into naive mice. These mice were treated with rapamycin for 25 days, and were challenged with VVGP33 on day 28 posttransfer. At 5 days after challenge, P14 expansion in spleen (g) and viral titres in ovary (h) were analysed (n 5 4-6; each group). Flow data were gated on CD8 T cells. Data show mean and s.e.m.
interference (RNAi) system to specifically knockdown various genes of the mTOR pathway (mTOR, raptor, S6K1 (also known as Rps6kb1), Eif4e and Fkbp12) in antigen-specific CD8 T cells. Retroviruses marked by GFP and expressing RNAi for a particular gene or a control retrovirus were used to infect LCMV specific transgenic CD8 T cells (P14 cells); these transduced cells were then adoptively transferred into naive mice, followed by LCMV infection (Supplementary Fig. 7a ). This system allows us to compare the phenotypic changes that occur during memory T-cell differentiation in GFP 1 retrovirus transduced versus GFP 2 non-transduced antigen-specific CD8 T cells in the same environment (that is, the same mouse; Supplementary Fig. 7b ). Thus, any differences in memory differentiation that are seen between these two cell populations can be ascribed to the intrinsic effects of that particular gene in antigenspecific T cells.
In the initial set of experiments, we knocked down mTOR itself in antigen-specific CD8 T cells. We found that mTOR RNAi retrovirustransduced GFP 1 P14 cells showed significantly higher expression of the canonical memory T-cell markers (CD127, CD62L, Bcl2, CD27) and lower expression of KLRG1 compared to non-transduced or control vector transduced P14 cells (Fig. 4a) . These data show that mTOR acts intrinsically in antigen-specific CD8 T cells to regulate memory differentiation. However, as mTOR forms two distinct complexes, the rapamycin-sensitive mTOR complex 1 (mTORC1) and the rapamycin-insensitive mTORC2 5 , mTOR knockdown does not completely mimic rapamycin treatment. To distinguish between these two pathways, we knocked down the gene, raptor, that is an essential component of the mTORC1 complex 21, 22 . As shown in Fig. 4b , inhibition of raptor in antigen-specific T cells gave results identical to those seen on knockdown of mTOR, thereby identifying the mTORC1 complex as the regulator of memory differentiation. To gain more insight into mechanisms by which mTOR regulates memory formation, we examined the role of S6K1 and eIF4E 5 . We found that knockdown of these mTORC1 downstream effectors significantly enhanced memory CD8 T-cell differentiation (Supplementary Fig. 8 ). Thus, our results show that mTOR is exerting its effect through these two downstream molecules.
To further explore the role of mTOR in T-cell intrinsic versus external effects on memory differentiation, we made rapamycininsensitive antigen-specific CD8 T cells by knockdown of the FKBP12 protein. This intracellular protein binds rapamycin and it is this FKBP12-rapamycin complex that inhibits the mTORC1 pathway. Thus, by knocking down FKBP12 in P14 CD8 cells, we made these cells insensitive to any intrinsic effects of rapamycin but the RNAi Fkbp12 RNAi -Rapa +Rapa P = 0.0139 P = 0.0025 P = 0.0144 P = 0.0053 P = 0.0006 P = 0.0002 P = 0.0001 P = 0.0062 P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0042 drug could still act effectively on all the other cells in the mouse. This system allows us to examine if inhibition of mTOR in other cells can effect memory CD8 T-cell differentiation. As shown in Fig. 4c , inhibiting mTOR in other cells when the antigen-specific cells themselves were rapamycin insensitive did not effect memory differentiation. The effect of rapamycin on memory differentiation almost disappeared on knockdown of FKBP12 from the P14 cells, and these cells did not show increased expression of the characteristic memory markers (CD127, CD62L, Bcl2, and so on; see rightmost column in Fig. 4c ). Thus, taken together, the results shown in Fig. 4a -c establish that mTOR not only acts intrinsically in antigen-specific CD8 T cells but that inhibiting mTOR in other cells has minimal to no effect on memory T-cell differentiation.
During the past few years, considerable progress has been made in understanding the lineage relationships between naive, effector and memory T cells and in defining the phenotypic and functional changes that underlie memory CD8 T-cell differentiation 1, 23 . However, much less is known about the intracellular molecules and pathways that regulate the generation of memory T cells. In this study, we identify a molecular pathway that regulates memory T-cell differentiation, and provide a strategy for modulating the formation of memory cells. In particular, the ability to increase the functional qualities of memory T cells provides a new approach for enhancing the efficacy of vaccines against infectious diseases and cancer.
METHODS SUMMARY
Mice, viral infection, and VLP. C57BL/6j mice and Thy-1.1 P14 transgenic mice bearing the H-2D b GP33 epitope specific TCR were used. Mice were intraperitoneally (i.p.) infected with LCMV Armstrong or recombinant vaccinia virus GP33 (VVGP33), which expresses the LCMV GP33 epitope. For VLP immunization, mice were subcutaneously given VLP genetically fused to LCMV GP33 epitope 18 . Rhesus macaques and vaccination. Six rhesus macaques were inoculated with Dryvax (Wyeth) by scarification. At 105 days post Dryvax vaccination, animals were then vaccinated intramuscularly (i.m.) with MVA. Administration of rapamycin. For the murine experiments, rapamycin (Wyeth) was administered i.p. daily. A relatively low dose of rapamycin was used during T-cell expansion phase because the higher dose inhibited T-cell responses ( Supplementary Fig. 9 ). For the rhesus macaque experiments, rapamycin was administered daily i.m. to Dryvax immunized animals before MVA vaccination. Generation and isolation of effector and memory T-cell subsets. Naive P14 transgenic T cells were adoptively transferred into B6 recipients (P14 chimaeric mice). Effector and memory P14 T cells were isolated from LCMV-infected P14 chimaeric mice. CD62L 2 effector CD8 T cells were purified using anti-CD62L magnetic beads and a CD8 T cell isolation kit (Miltenyi Biotec). Retrovirus based RNAi. The pMKO.1 GFP retroviral vector (Addgene plasmid 10676) was provided by W. Hahn. Double strand oligonucleotides for short hairpin RNA (shRNA) were cloned into pMKO.1 GFP. Recombinant retrovirus was made by transfection in 293T cells. Retrovirus transduced P14 cells were adoptively transferred into naive mice, then the mice were infected with LCMV Armstrong. The GFP 1 P14 CD8 T cells were purified by FACS on day 7-8 postinfection, and then protein expression levels were analysed by western blotting ( Supplementary Fig. 10 ).
